Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
MPA8801
Study information
Scientific title
Acronym
Study hypothesis
Not provided at time of registration
Ethics approval
Not provided at time of registration
Study design
Randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Not specified
Trial type
Not Specified
Patient information sheet
Condition
Head and Neck Cancer
Intervention
1. Group A: Oral medroxyprogesterone acetate 500 mg twice daily for a maximum of 12 weeks
2. Group B: Placebo tablets twice daily for a maximum of 12 weeks
Intervention type
Other
Phase
Not Specified
Drug names
Primary outcome measure
Not provided at time of registration
Secondary outcome measures
Not provided at time of registration
Overall trial start date
19/08/2000
Overall trial end date
19/08/2005
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Aged >18 years
2. Squamous cell carcinoma of the head and neck
3. Not known to have or suspected of having early breast cancer
4. No known hypersensitivity to medroxyprogesterone acetate
5. No medical contraindications to treatment
Participant type
Patient
Age group
Not Specified
Gender
Not Specified
Target number of participants
Not provided at time of registration
Participant exclusion criteria
Not provided at time of registration
Recruitment start date
19/08/2000
Recruitment end date
19/08/2005
Locations
Countries of recruitment
Italy
Trial participating centre
UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom
Funders
Funder type
Not defined
Funder name
Not provided at time of registration.
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Basic results (scientific)
Publication list